2Rocha R,Williams GH.Rationale for the use of Aldosterone antagonists in congestive heart failure[J]. Drugs, 2002, 62(5) : 723.
3Satoh M, Nakamura M, Saitoh H, et al .Aldostemne synthase(CYP11B2) expression and myocardial fibrosis in the failing human heart[J] . Clin Sci (Lond), 2002, 102(4) :381.
4McMahon EG. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist[J ]. Curr Opin Pharmacol ,2001,1(2) : 190.
5Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure[J]. Circulation, 2000, 102(22) :2 700.
6Struthers AD.Impact of aldosterone on vascular pathophysiology[J]. Congest Heart Fail ,2002.8(1):18.
7McKelvie RS, Yusuf S, Pe ricak D, et al .Comparison of candesartan, enalapril, and their combination in congestive heart failure: rondomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot Study Investigators[J] . Circulation, 1999,100(10) : 1 056.
8Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure[J ]. J Card Fail, 1996,2(1) :47.
9Sun Y,Zheng J, Zhang JQ, et al. Local angiotensin Ⅱ and transforming growth factor-betal in renal fibrosis of rats[J ] . Hypertension, 2000,35(5) : 1 078.
10Pitt B, Zannad F, Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with sever heart failure:Randomized Aldactone Evaluation Study Investigators[J] . N Engl J Med, 1999, 341(10) : 709.
